Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA

Agnieszka Dzikiewicz-Krawczyk1, Anna Macieja, Ewa Mały

  • 1Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland. krawczyk@man.poznan.pl.

Abstract

Insights

MicroRNA-binding site polymorphisms influence leukemia risk by altering microRNA interactions. Specific genetic variations in target genes are linked to increased or decreased risks for acute lymphoblastic leukemia and myeloid leukemias.

Area of Science:

  • Genetics
  • Molecular Biology
  • Oncology

Background:

  • MicroRNA (miRNA) dysregulation is a hallmark of leukemia.
  • Polymorphisms in miRNA-binding sites (miRSNPs) within target genes can affect miRNA-mRNA interactions and protein expression levels.

Purpose of the Study:

  • To identify miRSNPs associated with leukemia risk.
  • To evaluate the impact of identified miRSNPs on miRNA binding affinity to target transcripts.

Main Methods:

  • Bioinformatic analysis of 3' untranslated regions of 137 leukemia-associated genes to identify putative miRSNPs.
  • Genotyping of 87 acute myeloid leukemia (AML), 140 chronic myeloid leukemia (CML), 101 childhood acute lymphoblastic leukemia (ALL) patients, and 471 healthy controls.
  • Multivariate logistic regression for risk association analysis and luciferase reporter assays to confirm miRNA binding alterations.

Main Results:

  • Variant alleles of TLX1_rs2742038 and ETV6_rs1573613 were associated with increased childhood ALL risk.
  • PML_rs9479 was associated with decreased ALL and AML risk.
  • ARHGAP26_rs187729 and IRF8_rs10514611 variant alleles were linked to increased CML risk; functional assays confirmed altered miRNA binding for ARHGAP26_rs187729, PML_rs9479, and ETV6_rs1573613.

Conclusions:

  • MicroRNA-binding site polymorphisms modulate leukemia risk through interference with miRNA-mediated gene regulation.
  • Variability within the 3' untranslated regions of genes plays a significant role in leukemia pathogenesis.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.0K
MicroRNAs01:22

MicroRNAs

9.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K